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ABSTRACT
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) gastropathy is a common complication, which 
has characteristic symptoms of dyspepsia syndrome. Mostly, it includes epigastric discomfort with bloating 
and nausea. The aim of this study was to provide evidences that clinical symptoms of dyspepsia are related to 
macroscopic changes of gastric form in rats, which are expected to be applied in human.
Method: The study was conducted in 20 white rats (Rattus norvegicus, Sprague-Dawley strain) at 
the Department of Pathology and Clinical Reproduction, Bogor Agricultural University between January 
and December 2008. The rats were divided to treatment group and control group and each group consisted of 
10 rats. Acetyl salicylic acid (ASA/aspirin) was administered at 400 mg dose, diluted in distilled water and was 
given to the treatment group using gastric cannula, once daily for three days period; while the control group had 
received aquabidest only. Subsequently, necropsies were conducted for both groups, followed by macroscopic 
observation and measurement of sagittal and transversal diameter. Gastric incisions along the minor curvature 
were performed in both groups to recognize any macroscopic changes of gastric mucosa. ANOVA test was utilized 
for data analysis, which was followed by Duncan test when the results were significant.
Results: Gastric diameters in treatment group with positive lesion were significantly different from the control 
group and the treatment group with negative lesion on anthrum/pylorus region, with p < 0.05. 
Conclusion: Prominent gastric dilatation at anthrum/pylorus region found in the treatment group may become 
the initial cause and signs of dyspepsia in human.
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ABSTRAK
Latar belakang: Obat anti-inflamasi non steroid (OAINs) gastropati merupakan komplikasi yang sering 
ditemukan, yang mempunyai karakteristik gejala sindroma dispepsia dengan keluhan perasaan tidak nyaman 
di daerah epigastrium disertai kembung dan mual. Tujuan penelitian ini yaitu untuk membuktikan gejala klinis 
dispepsia terhadap perubahan pengamatan makroskopik pada lambung tikus diharapkan dapat mencerminkan 
pada manusia.
Metode: Penelitian ini dilakukan pada 20 ekor tikus putih Rattus norvegicus jenis Sprague-Dawley di Bagian 
Patologi dan Klinik Reproduksi, Institut Pertanian Bogor dari bulan Januari sampai Desember 2008. Tikus 
tersebut dibagi dalam dua kelompok; kelompok kontrol dan terapi. Aspirin yang dilarutkan air suling dengan 
dosis 400 mg diberikan pada kelompok terapi dengan kanul lambung, sekali sehari selama 3 hari. Sedangkan 
pada kelompok kontrol diberikan air suling saja. Sesudah itu dilakukan nekropsi terhadap kedua kelompok dan 
dilakukan pengamatan makroskopik lambung, serta dilanjutkan pengukuran diameter sagittal dan transversal. 
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Untuk mengetahui perubahan makroskopik mukosa lambung dilakukan insisi sepanjang kurvatura minor pada 
kedua kelompok. Analisis data dilakukan dengan tes ANOVA dan dilanjutkan dengan tes Duncan untuk hasil 
yang bermakna. 
Hasil: Diameter kelompok dengan terapi aspirin dengan lesi mukosa positif mempunyai perbedaan bermakna 
dengan kelompok kontrol, dan kelompok terapi aspirin lesi mukosa negatif pada regio antrum/pilorus, dengan 
nilai p < 0.05.
Kesimpulan: Dilatasi gaster dari kelompok tikus yang mendapat aspirin dengan lesi mukosa gaster regio 
antrum dapat menjadi model untuk melihat munculnya gejala dan tanda dispepsia pada manusia. 
Kata kunci: OAINs gastropati, dispepsia, NSAIDs/aspirin, dilatasi gaster
INTRODUCTION
Aspirin has been widely used for many clinical 
entities such as rheumatic diseases, heart diseases, 
stroke, and hematologic disorders. With a wide spectrum 
of indication, the use of aspirin is usually associated 
with gastrointestinal complication, especially on the 
stomach. The initial symptoms of such complication 
may appear syndrome of dyspepsia.1-5 Complications 
may occur in mild to severe form including gastric 
ulcer either with or without bleeding. In some cases, a 
more serious complication such as perforation probably 
present.5-7 In human, mostly it is difficult to determine 
the etiology of dyspepsia since we could not detect any 
macroscopic changes of the stomach directly. In animal 
experimental study, such problem could be solved since 
we could easily perform necropsy or tissue resection 
after the animal had been treated with aspirin. The 
necropsy would reveal the whole contour of stomach 
and mucosal lesion. Some studies have indicated 
that clinical symptoms are not directly associated 
with gastric mucosal abnormalities; however, the 
occurrence of gastric complication may be recognized 
through observation of clinical symptoms, including 
the dyspepsia syndrome.5,6,8
The hypothesis of this study was that aspirin 
would induce gastric mucosal lesions with initial 
sign of gastric dilatation, which may be related to 
dyspepsia symptoms. The most common symptoms 
are epigastric discomfort or epigastric pain, bloating, 
nausea and vomiting. If those symptoms persist, 
usually other symptoms may occur such as melena with 
or without hematemesis. Dyspepsia is initial symptom 
of nonsteroidal anti-inflammatory drug (NSAID) 
gastropathy, which may be related to gastric functions. 
The etiology of dyspepsia due to gastric dilatation may 
be associated with mucosal inflammation of anthrum. 
Gastric mucosal lesions caused by NSAID mostly 
occur as a result of direct contact between the drug 
and mucosa because of impaired mucus secretion. 
The condition is associated with the type of drugs, 
duration of drug contact to the mucosa, and the role of 
pH in gastric lumen. The durability of gastric mucosa 
is correlated with pre-epithelial, epithelial and sub-
epithelial component.8,9 The aim of this study was to 
provide evidences that clinical symptoms of dyspepsia 
are related to macroscopic changes of gastric form in 
rats which are expected to be applied in human.
METHOD
The animals used for this study work were 20 male 
white rats (Rattus norvegicus) of Sprague-Dawley 
strain. The rats were 2 months old and the average 
weight of each rat was ± 250 g. The animals obtained 
from the Department of Animal Production, Non 
Ruminant and Prospective Animal Division, Faculty 
of Animal Sciences, Bogor Agriculture University. 
The study was conducted at Department of Pathology 
and Clinical Reproduction, Faculty of Veterinary 
Science, Bogor Agricultural University, between 
January and December 2008. The animals were 
categorized into two groups, i.e. the control group 
and treatment group. Each group consisted of 10 rats. 
Acetyl salicylic acid (ASA/aspirin) at 400 mg 
dose diluted in distilled water was administered to 
the treatment group; while the control group was 
given distilled water only. Preliminary study, including 
adaptation and pre-treatment study had been conducted 
to minimize bias and to adjust factors that may affect 
gastric mucosa. Each rat was kept separately in 
a modified cage and the rats were fed ad libitum. 
The food was provided as pellet that had been treated 
with irradiation of 10 kGray to ensure sterility. 
In the three-week preliminary study, the rats were 
administered a dose of 250 mg/kgBW of tetracycline 
for three days and a single dose of albendazole 5%, 
an antihelminthic agent, once in a week. Subsequently, 
they were also given a dose of 50 mg/kgBW of 
fluconazole, an anti-cryptococcus, once daily for three 
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days. The weight of those rats and food pellet residue 
were calculated every day. ASA was administered 
orally to the rats in treatment group by using gastric 
cannula. Prior to ASA administration, the rats were 
having three-hour fasting, which subsequently 
followed by administration of 400 mg ASA dissolved 
in 2 ml distilled water once daily for three days. 
Afterwards, rats were sacrificed by performing 
necropsy in both groups using ether for anesthetic. 
Necropsy was initiated along the alba line by opening 
skin layer and fascia. The stomach was separated 
from its surrounding tissue and finally was detached. 
Before performing stomach incision, the sagittal and 
transversal diameters of stomach were measured. 
Quantitative data were analyzed using one-way 
ANOVA test and SPSS software version 13.0. ANOVA 
was utilized to compare control (C) group, treatment 
group with negative lesion (TNL) and treatment 
group with positive lesion (TPL). When the results 
were significant, it was followed by Duncan test, with 
p value of < 0.05.
RESULTS
The results of this study included measurement of 
sagittal and transversal gastric diameter (Table 1 and 
2) between C group, TNL group and TPL group, and 
macroscopic observation of gastric fundus/corpus 
(Figure 1 and 2). 
Table 1. Differences of diameter measurement between C, TNL, 
and TPL group on the fundus/corpus region
Diameter 
length
Fundus/corpus
C TNL TPL p
Sagittal 9.33+0.51 9.86+1.76 9.75+0.92 > 0.05
Transversal 4.29+0.28 4.77+0.92 4.40+0.14 > 0.05
*C: control; TNL: treated negative lesion; TPL: treated positive lesion
Table 2. Differences of diameter measurement between C, TNL, 
and TPL group on the antrum/pylorus region
Diameter 
length
Antrum/pylorus
C TNL TPL
Sagittal 9.33+0.51a 8.75+1.29a 10.70+1.22b
Transversal 4.29+0.28a 4.28+0.29a 5.20+1.02b
* C: control; TNL: treated negative lesion; TPL: treated positive lesion; *the 
different alphabet shows p < 0.05
(a) (b)
DISCUSSION
This study would explain more thoroughly about 
the length of contact between aspirin and gastric 
mucosal. The length of the contact time depend on 
the gastric mucosal condition. The initial process 
of gastric lesion due to inflammation, continued 
by discharge of inflammatory mediators result to 
edematous mucosa. This condition will be occured 
delayed gastric emptying. Mucosal lesion occur more 
faster, due to prolong time contact between the drug 
and the mucosal. Inflammatory cell, which is one 
of defensive factors, will increase on the mucosal 
layer that will be infiltrated the layer, especially on 
muscularis mucosa area, followed by its surrounding 
tissue edema, therefore gastric motility will be 
decreased. This condition can affect the gastric shape 
due to gastric emptying disorder. If these symptoms 
persist, gastric dilatation is likely to occur. This 
condition related to clinical symptoms, likely motility 
disturbances. Gastric dysmotility will be influenced 
gastric emptying. The occurrence of mucosal lesion 
due to aspirin is determined by the pre-epithelial 
Figure 1. Macroscopic abnormalities of whole stomach part (a) 
and incised part of stomach (b) with dilatation 
(a) (b)
Figure 2. Normal macroscopic appearance of whole stomach 
part (a) and incised part of stomach (b)
Statistically, there was significant difference of 
gastric sagittal and transversal diameter between TPL 
and C or TNL group. However, no significant difference 
was found regarding sagittal and transversal diameter 
between TNL and C group (Table 2).
The contour of the rat stomach in treatment group 
was found to have gastric dilatation, both in sagittal 
and transversal diameter, especially in anthrum/pylorus 
region.
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condition, especially the mucus function as the fore 
mucosal barrier.7,8,10 
Previous studies show that the occurrence of 
gastrointestinal side effect caused by NSAIDs is 
usually based on clinical symptoms. The most 
common side effect is dyspepsia syndrome. Epigastric 
discomfort with or without pain, bloating, nausea and 
vomiting are common symptoms of gastric disorder.1-5 
This study was aimed to reveal the pathophysiology 
of dyspepsia, which has not been done before since 
the contour of human stomach could not be seen 
clearly. This study has been performed in white rats, 
an animal experimental study, which the results are 
expected to be applied in human.
This study has revealed altered gastric contour in 
treatment group with mucosal lesion. Such changes 
may be associated with infiltration of inflammatory 
cells, especially the mucosal neutrophils which 
have reached epithelial cells. Inflammatory cells in 
the muscularis mucosa layer and tissue edema may 
affect stomach motility.5,6,7 Furthermore, it may cause 
impaired gastric clearance and gastric emptying 
leading to accumulation of gastric content, including 
aspirin. The risk is greater when there is longer duration 
of contact between the drug and gastric mucosa, which 
may induce the development of mucosal lesion. This 
study showed that there was increased length of 
sagittal and transversal diameter in the treatment group 
with mucosal lesion. Although gastric dilatation was 
observed on the mucosal lesion of corpus/pylorus, but 
there was no significant difference of gastric diameter 
between the treatment group without lesion and 
the control group. It could be explained since mucosal 
lesion on anthrum/pylorus region are more frequently 
found than corpus/pylorus region; therefore, it may be 
associated with the clearance of anthrum region and 
the duration of aspirin exposure on gastric mucosa.7,11 
CONCLUSION
Dyspepsia syndrome is a collection of initial 
symptoms that may reveal the occurrence of 
gastrointestinal complication associated with NSAIDs. 
The syndrome may be caused by gastric dilatation 
and as result of motility disorder, which may delay 
clearance of gastric contents from antrum to duodenum. 
The occurrence of mucosal lesion is affected by 
the length of aspirin exposure on gastric mucosa. 
Prominent gastric dilatation at anthrum/pylorus region 
found in the treatment group of this study may become 
the initial cause and signs of dyspepsia in human.
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